Literature DB >> 27505669

Sticking It to Cancer with Molecular Glue for SHP2.

Hao Ran1, Ryouhei Tsutsumi1, Toshiyuki Araki1, Benjamin G Neel2.   

Abstract

Much effort has been expended to develop inhibitors against protein-tyrosine phosphatases (PTPs), nearly all of it unsuccessful. A recent report, describing a highly specific, orally bioavailable inhibitor of the PTP oncoprotein SHP2 with in vivo activity, suggests that allostery might provide a way forward for PTP inhibitor development.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27505669      PMCID： PMC5558882          DOI： 10.1016/j.ccell.2016.07.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  9 in total

Review 1.  Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2.

Authors:  D Barford; B G Neel
Journal:  Structure       Date:  1998-03-15       Impact factor: 5.006

Review 2.  FDA-approved small-molecule kinase inhibitors.

Authors:  Peng Wu; Thomas E Nielsen; Mads H Clausen
Journal:  Trends Pharmacol Sci       Date:  2015-05-12       Impact factor: 14.819

Review 3.  Small molecule tools for functional interrogation of protein tyrosine phosphatases.

Authors:  Rongjun He; Li-Fan Zeng; Yantao He; Sheng Zhang; Zhong-Yin Zhang
Journal:  FEBS J       Date:  2012-08-16       Impact factor: 5.542

Review 4.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 5.  Protein tyrosine phosphatases in cancer: friends and foes!

Authors:  David P Labbé; Serge Hardy; Michel L Tremblay
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

6.  Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.

Authors:  Ying-Nan P Chen; Matthew J LaMarche; Ho Man Chan; Peter Fekkes; Jorge Garcia-Fortanet; Michael G Acker; Brandon Antonakos; Christine Hiu-Tung Chen; Zhouliang Chen; Vesselina G Cooke; Jason R Dobson; Zhan Deng; Feng Fei; Brant Firestone; Michelle Fodor; Cary Fridrich; Hui Gao; Denise Grunenfelder; Huai-Xiang Hao; Jaison Jacob; Samuel Ho; Kathy Hsiao; Zhao B Kang; Rajesh Karki; Mitsunori Kato; Jay Larrow; Laura R La Bonte; Francois Lenoir; Gang Liu; Shumei Liu; Dyuti Majumdar; Matthew J Meyer; Mark Palermo; Lawrence Perez; Minying Pu; Edmund Price; Christopher Quinn; Subarna Shakya; Michael D Shultz; Joanna Slisz; Kavitha Venkatesan; Ping Wang; Markus Warmuth; Sarah Williams; Guizhi Yang; Jing Yuan; Ji-Hu Zhang; Ping Zhu; Timothy Ramsey; Nicholas J Keen; William R Sellers; Travis Stams; Pascal D Fortin
Journal:  Nature       Date:  2016-06-29       Impact factor: 49.962

7.  PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

Authors:  Anirudh Prahallad; Guus J J E Heynen; Giovanni Germano; Stefan M Willems; Bastiaan Evers; Loredana Vecchione; Valentina Gambino; Cor Lieftink; Roderick L Beijersbergen; Federica Di Nicolantonio; Alberto Bardelli; Rene Bernards
Journal:  Cell Rep       Date:  2015-09-10       Impact factor: 9.423

8.  Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.

Authors:  Navasona Krishnan; Dorothy Koveal; Daniel H Miller; Bin Xue; Sai Dipikaa Akshinthala; Jaka Kragelj; Malene Ringkjøbing Jensen; Carla-Maria Gauss; Rebecca Page; Martin Blackledge; Senthil K Muthuswamy; Wolfgang Peti; Nicholas K Tonks
Journal:  Nat Chem Biol       Date:  2014-05-20       Impact factor: 15.040

Review 9.  Noonan syndrome.

Authors:  Amy E Roberts; Judith E Allanson; Marco Tartaglia; Bruce D Gelb
Journal:  Lancet       Date:  2013-01-10       Impact factor: 79.321
  9 in total
  26 in total

1.  Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment.

Authors:  P Xiao; Y Guo; H Zhang; X Zhang; H Cheng; Q Cao; Y Ke
Journal:  Oncogene       Date:  2018-05-24       Impact factor: 9.867

2.  Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents.

Authors:  Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
Journal:  Hepatobiliary Surg Nutr       Date:  2020-12       Impact factor: 7.293

3.  PPP2R2B downregulation is associated with immune evasion and predicts poor clinical outcomes in triple-negative breast cancer.

Authors:  Zheng Li; Yaming Li; Xiaolong Wang; Qifeng Yang
Journal:  Cancer Cell Int       Date:  2021-01-06       Impact factor: 5.722

4.  PTPN2: a tumor suppressor you want deleted?

Authors:  Florian Wiede; Tony Tiganis
Journal:  Immunol Cell Biol       Date:  2017-10-10       Impact factor: 5.126

Review 5.  Functional interrogation and therapeutic targeting of protein tyrosine phosphatases.

Authors:  Aaron D Krabill; Zhong-Yin Zhang
Journal:  Biochem Soc Trans       Date:  2021-08-27       Impact factor: 5.407

6.  Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors.

Authors:  Lester J Lambert; Celeste Romero; Douglas J Sheffler; Maria Celeridad; Nicholas D P Cosford; Lutz Tautz
Journal:  J Vis Exp       Date:  2020-07-17       Impact factor: 1.355

7.  SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.

Authors:  Carmine Fedele; Hao Ran; Brian Diskin; Wei Wei; Jayu Jen; Mitchell J Geer; Kiyomi Araki; Ugur Ozerdem; Diane M Simeone; George Miller; Benjamin G Neel; Kwan Ho Tang
Journal:  Cancer Discov       Date:  2018-07-25       Impact factor: 39.397

8.  A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.

Authors:  Celeste Romero; Lester J Lambert; Douglas J Sheffler; Laurent J S De Backer; Dhanya Raveendra-Panickar; Maria Celeridad; Stefan Grotegut; Socorro Rodiles; John Holleran; Eduard Sergienko; Elena B Pasquale; Nicholas D P Cosford; Lutz Tautz
Journal:  J Biol Chem       Date:  2020-01-17       Impact factor: 5.157

9.  Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth.

Authors:  Yuyi Wang; Ombretta Salvucci; Hidetaka Ohnuki; Andy D Tran; Taekyu Ha; Jing-Xin Feng; Michael DiPrima; Hyeongil Kwak; Dunrui Wang; Yanlin Yu; Michael Kruhlak; Giovanna Tosato
Journal:  EMBO Mol Med       Date:  2021-06-08       Impact factor: 12.137

10.  Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC.

Authors:  Kwan Ho Tang; Shuai Li; Kwok-Kin Wong; Benjamin G Neel; Alireza Khodadadi-Jamayran; Jayu Jen; Han Han; Kayla Guidry; Ting Chen; Yuan Hao; Carmine Fedele; John A Zebala; Dean Y Maeda; James G Christensen; Peter Olson; Argus Athanas; Cynthia A Loomis; Aristotelis Tsirigos
Journal:  Cancer Discov       Date:  2021-08-05       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.